Ubs Oconnor LLC Glaukos Corp Transaction History

Ubs Oconnor LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$69.23 - $79.09 $1.38 Million - $1.58 Million	-20,000 Reduced 49.42%	20,471 $1.54 Million
Q2 2023 Aug 14, 2023	BUY	$45.44 - $71.21 $1.84 Million - $2.88 Million	40,471 New	40,471 $2.88 Billion
Q1 2023 May 15, 2023	BUY	$43.88 - $52.48 $285,702 - $341,697	6,511 Added 14.08%	52,738 $2.64 Million
Q4 2022 Feb 14, 2023	BUY	$40.82 - $57.75 $552,498 - $781,646	13,535 Added 41.4%	46,227 $0
Q3 2022 Nov 14, 2022	SELL	$46.84 - $58.49 $365,352 - $456,222	-7,800 Reduced 19.26%	32,692 $1.74 Billion
Q2 2022 Aug 12, 2022	BUY	$34.86 - $63.77 $1.09 Million - $2 Million	31,337 Added 342.29%	40,492 $1.84 Million
Q1 2022 May 16, 2022	BUY	$44.33 - $57.82 $405,841 - $529,342	9,155 New	9,155 $529,000

340

47.1M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $6.73B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.